EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia

Adalucy Alvarez-Aldana iD, Paula Andrea Fernandez Uribe, Tatiana Mejía Valencia, Yina Marcela Guaca-Gonzalez, Jorge Javier Santacruz-Ibarra, Brenda Lucia Arturo-Arias, Luis Javier Castañeda-Chavez, Robinson Pacheco-López, Lina María Londoño-Giraldo iD, José Ignacio Moncayo-Ortiz

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.00401-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Adalucy Alvarez-Aldana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Microbiología y Biotecnología (MICROBIOTEC), Universidad Libre Seccional Pereira, Pereira, Colombia. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Anti-Bacterial Agents, Microbial Sensitivity Tests. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Tecnológica de Pereira (UTP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. H. pylori positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for H. pylori by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for H. pylori . Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% P = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen. IMPORTANCE Antibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%–19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter pyloriHelicobacter InfectionsAnti-Bacterial AgentsMicrobial Sensitivity TestsDrug Therapy, CombinationClarithromycinAmoxicillinHumansColombiaMaleFemaleMiddle AgedAdultAgedProton Pump InhibitorsDrug Resistance, BacterialYoung AdultMetronidazoleLevofloxacinTreatment Outcome

Stichwörter der Autor:innen

ColombiaHelicobacter pyloriantibioticsdrug therapyeradicationresistance

Substanzen

Anti-Bacterial AgentsClarithromycinAmoxicillinProton Pump InhibitorsMetronidazoleLevofloxacin

Autor:innen und Institutionen

  • Grupo de Investigación en Microbiología y Biotecnología (MICROBIOTEC), Universidad Libre Seccional Pereira, Pereira, Colombia.
  • Grupo de Investigación ESCULAPIO, Universidad Libre Seccional Cali, Cali, Colombia.
  • Grupo de Investigación en Gerencia del Cuidado, Universidad Libre Seccional Pereira, Pereira, Colombia.
  • Grupo de Investigación en Enfermedades Infecciosas (GRIENI), Universidad Tecnológica de Pereira, Pereira, Colombia.
  • Grupo de Investigación Médica, Universidad de Manizales, Manizales, Colombia.
  • SES Hospital Universitario de Caldas, Manizales, Colombia.

ORCID-Profile: Adalucy Alvarez-Aldana, Lina María Londoño-Giraldo

Förderung

  • Universidad Tecnológica de Pereira (UTP)

Zitieren

APA

Alvarez-Aldana, A., Fernandez Uribe, P. A., Mejía Valencia, T., Guaca-Gonzalez, Y. M., Santacruz-Ibarra, J. J., Arturo-Arias, B. L., Castañeda-Chavez, L. J., Pacheco-López, R., Londoño-Giraldo, L. M., & Moncayo-Ortiz, J. I. (2024). Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00401-24

Vancouver

Alvarez-Aldana A, Fernandez Uribe PA, Mejía Valencia T, Guaca-Gonzalez YM, Santacruz-Ibarra JJ, Arturo-Arias BL, et al. Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00401-24

BibTeX
@article{AlvarezAldana2024,
  author = {Alvarez-Aldana, Adalucy and Fernandez Uribe, Paula Andrea and Mejía Valencia, Tatiana and Guaca-Gonzalez, Yina Marcela and Santacruz-Ibarra, Jorge Javier and Arturo-Arias, Brenda Lucia and Castañeda-Chavez, Luis Javier and Pacheco-López, Robinson and Londoño-Giraldo, Lina María and Moncayo-Ortiz, José Ignacio},
  title = {Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.00401-24}
}
Kostenlos starten →